



#2 04CO

OIPE

ENTERED

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/728,173DATE: 12/18/2000
TIME: 14:06:22Input Set : A:\98-104.app
Output Set: N:\CRF3\12182000\I728173.raw

3 <110> APPLICANT: Kuida, Keisuke (US only)
4 Flavell, Richard A. (US only)
5 Vertex Pharmaceuticals, Inc.
6 Yale University
8 <120> TITLE OF INVENTION: CASPASE-9 DEFICIENT ANIMALS AND THE USE THEREOF
10 <130> FILE REFERENCE: Caspase-9 Knockout
C--> 12 <140> CURRENT APPLICATION NUMBER: US/09/728,173
C--> 13 <141> CURRENT FILING DATE: 2000-12-01
15 <150> PRIOR APPLICATION NUMBER: US 60/087,711
16 <151> PRIOR FILING DATE: 1998-06-02
18 <160> NUMBER OF SEQ ID NOS: 7
20 <170> SOFTWARE: PatentIn Ver. 2.0
22 <210> SEQ ID NO: 1
23 <211> LENGTH: 22
24 <212> TYPE: DNA
25 <213> ORGANISM: Artificial Sequence
27 <220> FEATURE:
28 <223> OTHER INFORMATION: Description of Artificial Sequence:
29 oligonucleotide primer
31 <400> SEQUENCE: 1
32 atggacgaag cggatcggcg gc 22
34 <210> SEQ ID NO: 2
35 <211> LENGTH: 21
36 <212> TYPE: DNA
37 <213> ORGANISM: Artificial Sequence
39 <220> FEATURE:
40 <223> OTHER INFORMATION: Description of Artificial Sequence:
41 oligonucleotide primer
43 <400> SEQUENCE: 2
44 ttatgatgtt ttaagaaaa g 21
46 <210> SEQ ID NO: 3
47 <211> LENGTH: 24
48 <212> TYPE: DNA
49 <213> ORGANISM: Artificial Sequence
51 <220> FEATURE:
52 <223> OTHER INFORMATION: Description of Artificial Sequence:
53 oligonucleotide primer
55 <400> SEQUENCE: 3
56 gccatggacg aagcggatcg gcgg 24
58 <210> SEQ ID NO: 4
59 <211> LENGTH: 24
60 <212> TYPE: DNA
61 <213> ORGANISM: Artificial Sequence
63 <220> FEATURE:
64 <223> OTHER INFORMATION: Description of Artificial Sequence:
65 oligonucleotide primer
67 <400> SEQUENCE: 4

RECEIVED
JAN - 2 2001
OIPE/JCWS

RAW SEQUENCE LISTING DATE: 12/18/2000
 PATENT APPLICATION: US/09/728,173 TIME: 14:06:22

Input Set : A:\98-104.app
 Output Set: N:\CRF3\12182000\I728173.raw

68 ggcctggatg aaqaagagct tggg 24
 70 <210> SEQ ID NO: 5
 71 <211> LENGTH: 24
 72 <212> TYPE: DNA
 73 <213> ORGANISM: Artificial Sequence
 75 <220> FEATURE:
 76 <223> OTHER INFORMATION: Description of Artificial Sequence:
 77 oligonucleotide primer
 79 <400> SEQUENCE: 5
 80 ggggaagatgg atgcaaaaagc tcga 24
 82 <210> SEQ ID NO: 6
 83 <211> LENGTH: 24
 84 <212> TYPE: DNA
 85 <213> ORGANISM: Artificial Sequence
 87 <220> FEATURE:
 88 <223> OTHER INFORMATION: Description of Artificial Sequence:
 89 oligonucleotide primer
 91 <400> SEQUENCE: 6
 92 atggctgcaa ttcttctctg taag 24
 94 <210> SEQ ID NO: 7
 95 <211> LENGTH: 5
 96 <212> TYPE: PRT
 97 <213> ORGANISM: mammalian
 99 <220> FEATURE:
 100 <221> NAME/KEY: UNSURE
 101 <222> LOCATION: (4)
 102 <223> OTHER INFORMATION: X is arginine or glycine
 104 <220> FEATURE:
 105 <221> NAME/KEY: DOMAIN
 106 <222> LOCATION: (1)..(5)
 107 <223> OTHER INFORMATION: Pentapeptide motif common to all known cactases
 109 <400> SEQUENCE: 7
 110 Gln Ala Cys Xaa Gly
 111 1 5

VERIFICATION SUMMARY DATE: 12/18/2000
PATENT APPLICATION: US/09/728,173 TIME: 14:06:23

Input Set : A:\98-104.app
Output Set: N:\CRF3\12182000\I728173.raw

L:12 M:270 C: Current Application Number differs, Replaced Application Number
L:13 M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:110 M:341 W: (46) "n" or "Xaa" used, for SEQ ID:7